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Background: The FDA have recently published draft guidance for the development of treatments for early Alzheimer’s
disease. Key features of this guidance are the advocacy of sensitive cognitive measures and a taxonomy of disease
severity. Whilst desirable patterns of cognitive-functional improvement are included, specific measures, and the
magnitude of required effects, are not described.
Main section: We describe key elements of the guidance content, especially with regard targeting key cognitive
domains and the means by which they might be efficiently indexed in the disease stages included in the guidance.
We discuss also the opportunities to assess cognitive performance in ‘Stage 2’ and ‘Stage 3’ patients, as well as the
possibilities for effectively assessing function in the latter category. In this section we review candidate cognitive
assessments that we judge are capable of delivering on the guidance specification for sensitive neuropsychological
measures. This includes detailed consideration of the ADCS-PACC and Catch-Cog initiatives. With respect to the
magnitude of effects, we propose that standardised effect sizes of 0.3 represent a reasonable level of efficacy based on
the observation that already marketed drugs on average deliver this level of improvement.
Conclusions: We propose the use of cognitive measures in stage 2 patients to index the cognitive skills known to be
compromised early in the Alzheimer’s disease process. We recommend extending the traditional interest in episodic
memory to include sensitive, reliable and valid measures of attention, working memory and aspects of executive
function. We propose a focus on these additional cognitive abilities based on evidence that performance on tests of
these domains is moderately well related to functional skills.
Keywords: Cognition, Dementia, Memory, Attention, Neuropsychological, Alzheimers, Executive
Background
The FDA has recently published a new guidance note
for developing drugs to treat early Alzheimer’s disease
(AD) [1]. The guidance is as significant for what it
doesn’t contain, as much as its actual content. For
example, neither the ADAS-cog [2] nor the CDR-SB [3]
are mentioned. One interpretation of this is that the
agency recognises the risk that the mere mention of a
test to illustrate a point will be seen as a specific en-
dorsement of that measure. The absence of the CDR-SB
will come as no surprise to those of us who attended the
CTAD session at which an agency employee indicated
that this would be the case. So much for what is absent,
but what is actually in the document? The authors
include guidance on the use of biomarkers and other
aspects of drug development that will not be discussed
here. However, cognitive assessment, and a four-stage
taxonomy of disease progression are extensively
discussed, and it is these topics that will be the focus of
our consideration.
General issues raised in the new guidance
The preamble to the guidance includes a helpful
reminder that whilst we have tended to dichotomise
cognition and function, the two are inextricably linked:
‘FDA rejects this dichotomy and finds such usage in-
appropriate, because it implies that an effect on cognition
itself, regardless of the nature of the observed effect and
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the manner in which it is assessed, cannot be clinically
meaningful. This is certainly not the case’.
A question this raises is how do we define what might
be ‘clinically meaningful’? The guidance includes refer-
ence to cognitive changes ‘of a particular character,
perhaps defined by magnitude or breadth of effect(s),
may represent clinically meaningful benefit’. This issue
has been a topic of discussion for some time and was
considered by a number of us in a recent paper [4]. We
will return to the topic of clinical meaningfulness later.
Types of patients – a proposed taxonomy
Turning to the staging taxonomy, Stage 1 patients are in
part defined as having no ‘detectable abnormalities on
sensitive neuropsychological measures’. However, Stage
2 patients are defined as those who exhibit ‘detectable
abnormalities on sensitive neuropsychological measures’
but in whom ‘there is no evidence of functional impair-
ment’. The authors suggest in the context of Stage 2
patients that the ‘FDA will consider strongly justified ar-
guments that a persuasive effect on sensitive measures
of neuropsychological performance may provide ad-
equate support for a marketing approval’. The authors
suggest that a persuasive effect could be based on ‘A
pattern of putatively beneficial effects demonstrated
across multiple individual tests’.
Stage 3 patients are in part defined as exhibiting
‘subtle or more apparent detectable abnormalities on
sensitive neuropsychological measures, and mild but de-
tectable functional impairment’. The authors describe
Stage 3 as ‘Early AD patients approaching the onset of
overt dementia’ who are likely to have relatively mild but
noticeable impairments in their daily functioning. The
authors suggest that as with Stage 2 patients, ‘studies in
this stage of disease will generally include sensitive
measures of neuropsychological performance’. However,
they recognise that this performance may be ‘of uncer-
tain independent clinical meaningfulness’ and thus in
their view ‘it is important to demonstrate that a drug
favorably affects these functional deficits’.
The assessment of Stage 2 Patients
So much for the guidance review, what might this mean
in practice, and how might drug development sponsors
respond? In the context of Stage 2 patients, in whom
there are detectable cognitive but not functional deficits,
we might sensibly employ a cognitive assessment that
indexes the relevant domains of function. A number of
such assessments have been developed and include
computerised assessments, as well as traditional ‘paper--
and-pencil’ (P&P) testing. Irrespective of the delivery
platform the proposed assessments have tended to con-
verge on the domains of episodic memory, working
memory, and aspects of executive function. This focus
has a long history and specific reference to these do-
mains was included in the 2008 European Task Force
guidance [5]. A very similar approach was adopted by
the EPAD Scientific Advisory Group for Clinical and
Cognitive Outcomes [6]. Specific examples of cognitive
assessments that include measures of these domains are
the Alzheimer Disease Cooperative Study Preclinical
Alzheimer Cognitive Composite (ADCS-PACC) [7] and
Catch-Cog [8] initiatives, both of which will be discussed
in detail later in this paper. These assessments are
composed of P&P measures, some of which have
been combined with computerised assessments, as in
the case of recently completed studies such as the
one reported by Probiodrug [9], and in ongoing stud-
ies being conducted by companies such as Axon
Neuroscience [10]. Whilst the content of these assess-
ments has a similar conceptual basis, the specific
composition of these assessments varies markedly.
However, they converge with respect to exhibiting re-
spectable levels of reliability, validity and sensitivity,
and the domains of cognition they index. The guid-
ance offered by Ferris et al. [11] and Harrison [12]
provides the means for selecting appropriate mea-
sures. In the following section, we will describe
current projects focused on developing novel and
more comprehensive assessments of cognition. In the
course of this description we will appraise these mea-
sures in the context of best practice guidance.
ADCS-PACC
The ADCS-PACC is one of a number of composite
cognitive measures employed in ongoing studies of early
or preclinical AD [7]. It is a response to concerns that
standard AD measures are likely to prove insensitive to
early stage deficits and to cognitive change, whether as a
function of disease progression and/or therapeutic inter-
vention. The tests that comprise the ADCS-PACC have
been selected to index primarily episodic memory, hence
the inclusion of the Free and Cued Selective Reminding
Test (FCSRT [13]) and the Logical Memory IIa sub-test
from the Wechsler Memory Scale [14]. The former test
yields a score of 0-48 and the latter from 0 to 25. Mem-
ory in the form of orientation is measured using the
MMSE [15]. The fourth and final ADCS-PACC measure
is the Digit Symbol Substitution Test (DSST) from the
WAIS-R [16]. This has been selected by the authors as a
measure of executive function, though the DSST is
popularly regarded as measuring a number of cognitive
functions, including both attention and working mem-
ory. The performance range for the DSST varies between
0 and 93.
The four components of the ADCS-PACC are all
scored on different ranges and so in order to make per-
formance on all four measures directly comparable a
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composite score of all ADCS-PACC tests is calculated
using a z-score normalization method. Each of the four
component change scores is divided by the baseline
sample standard deviation of that component, to form
standardized z-scores. These z-scores are summed to
form the composite.
The tests that comprise the ADCS-PACC have a pedi-
gree of use in various cross-sectional and longitudinal
studies of patients with AD. The most notable of these
is probably the ADNI group of studies. The cognitive
focus of the assessment meets the requirement for mea-
sures of episodic memory, working memory and ele-
ments of executive function. The inclusion of the DSST
also allows for praxis and attention to be assessed. The
tests selected meet current best practice guidance and
promise much as measures of longitudinal cognitive
change. The ADCS-PACC has yet to demonstrate sensi-
tivity to pharmacological treatment effects in studies of
putative therapies for AD. However, the DSST has previ-
ously shown beneficial treatment effects in MCI [17]. A
second key issue is whether the rates of cognitive change
seen on these measures, when incorporated in assess-
ments featuring multiple other tests, will be replicated
when solely the ADCS-PACC measures are adminis-
tered. This is a key element of validation and a question
that must be asked of all new cognitive assessment tools,
whether composed of entirely new tests, or measures
that have been employed in previously conducted
studies.
Catch-Cog
A further approach is the possibility of employing mea-
sures that comprise traditional AD trial metrics, such as
the ADAS-cog, NTB, etc. We have considerable experi-
ence with the use of these measures and an abundance
of data with which to judge their sensitivity and reliabil-
ity [18, 19]. A further advantage of this approach is that
they are familiar to the drug development community,
including trial sites, regulators, and other interested
third parties. Repurposing well-known tests is therefore
a tempting proposition. Catch-Cog is a composite score
that blends memory components of the ADAS-cog with
executive function measures from the NTB and
ADCS-PACC [8]. Amongst the ADAS-cog subtests
Word Recall, Word Recognition, and Orientation are
substantially less prone to range restrictions than the
other ADAS-cog measures (see Table 1) and have signifi-
cant potential for capturing progressive decline in epi-
sodic memory and treatment effects. A point of note is
that in contrast to the other ADAS-cog subtests, the
Orientation test is naturally, if only partially, parallel in
nature, and through the use of parallel word lists the
Word Recall and Word Recognition stimuli can be var-
ied across visits.
An acknowledged deficiency of the ADAS-cog is the
lack of quality measures of attention, working memory
and executive function [20–22]. Valid and sensitive
measures of these functions have been extensively
employed in other composite measures [23]. For
example, Catch-Cog includes the COWAT & CFT from
the NTB, both of which are well-known and extensively
validated tests of working memory and executive
function [24]. These measures have also previously been
shown to be sensitive to treatment effects, most obvi-
ously in the PBT2 [25] and Encenicline [26] studies. The
final cognitive Catch-Cog measure is the Digit Symbol
Substitution Test (DSST). As discussed above, this test
has a number of virtues, including brevity (about two
minute duration) as well as the capacity to measure a
variety of cognitive skills, including attention and work-
ing memory. It is also acknowledged as a test of ‘timed
executive function’ by the CHMP of the EMA [27]. As
mentioned, this measure yielded a significant benefit of
treatment with galanthamine in MCI [17] and has been
observed to be a sensitive measure of treatment effects
in other CNS indications [28].
The philosophy underlying selection of the Catch-Cog
assessment is that robust, reliable, sensitive and valid
measures will yield an efficient, evidence-based assess-
ment of cognitive change. The selection of measures that
index performance in clinically relevant skills, known to
be compromised early in the Alzheimer’s disease
process, meets expert group guidance on cognitive
assessment. A further dimension of the Catch-Cog
research program is that the Amsterdam Instrumental
Activities of Daily Living [29] is being validated along-
side the cognitive composite.
The measures selected for inclusion in Catch-Cog have
a rich provenance for capturing treatment effects. The
NTB executive function tests have previously performed
well in studies of the PBT2 [30], as well as the Enceni-
cline study mentioned above. A remaining but critical
question for Catch-Cog is the extent to which it demon-
strates robust psychometric characteristics, such as
temporal reliability and the assessment’s capacity to
show longitudinal change. Both issues are under active
investigation. Given that the measures that comprise the
Catch-Cog have independently exhibited robust psycho-
metric attributes, acceptable levels of performance are
anticipated in the validation study [31]. A summary of
the cognitive domains and processes indexed by
Catch-Cog, the ADCS-PACC, and ADAS-cog is shown
in Table 1.
So, what would the FDA find ‘persuasive’ enough with
respect to these measures to grant marketing approval
for Stage 2 patient treatment? This is not specified,
though the guidance authors suggest that this requires
‘A pattern of putatively beneficial effects demonstrated
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across multiple individual tests’ and that ‘A large
magnitude of effect on sensitive measures of neuro-
psychological performance may also increase their per-
suasiveness’. The former requirement is the pattern of
performance seen in recent studies of cognitive benefits
of new multimodal anti-depressant drugs [32], captured
using cognitive assessments the content of which is very
similar to the above examples. The guidance authors do
not provide an indication of how substantive a treatment
would have to be. Currently marketed drugs yield posi-
tive cognitive effect sizes of about 0.3 [33] and we are
necessarily left to speculate what the agency would
regard as acceptable evidence. Intuitively we suspect that
a standalone cognitive effect of a symptomatic relieving
treatment might require positive effect sizes of at least
0.3 across a number of domains, with a 0.5 positive ef-
fect in a key area, such as episodic or working memory.
Now we turn to consider Stage 3 Patients, in whom
the focus is on cognitive-functional impairment. Cogni-
tive assessment is still ‘front and centre’ and the authors
specify that ‘Ideally, the outcome measure used in this
stage of disease will provide an assessment of meaning-
ful cognitive function’. With respect to function, the
authors point out that ‘Many of the assessment tools
typically used to measure functional impairment in pa-
tients with overt dementia may not be suitable for use in
these early stage patients’. They are presumably referring
here to traditionally employed ADL assessments such as
the DAD [34] and ADCS-ADL [35]. Consistent with past
advice, the guidance authors allow for the use of ‘An in-
tegrated scale that adequately and meaningfully assesses
both daily function and cognitive effects in early AD
patients’ which would be ‘acceptable as a single primary
efficacy outcome measure’. The inclination of sponsors
with regard the selection of an integrated scale has been
to employ the CDR-SB. This new guidance neither
endorses nor prohibits the use of the CDR-SB. However,
it is perhaps significant that the authors state that:
‘FDA encourages the development of novel approaches
to the integrated evaluation of subtle early AD (prede-
mentia) functional deficits/impact that arise from early
cognitive impairment (e.g., facility with financial transac-
tions, adequacy of social conversation)’.
One supposes that this exhortation would be unneces-
sary if the CDR-SB was considered to be the sole accept-
able solution to the need for a cognitive-functional
measure. EMA has previously cautioned [36] that ‘The
CDR-SB scoring requires extensive training and is
subject to variability among ethnicity and languages’. It
might be that current initiatives, such as Catch-Cog, in
which we are seeking to validate the combined use of
the more robust cognitive measures used in AD trials
with the Amsterdam IADL will provide helpful alterna-
tives to the use of the CDR-SB.
On a final topic, where does this new guidance leave
us with respect to use of the ADAS-cog? A generous in-
terpretation of the ADAS-cog’s utility is that it does a
not bad job of measuring episodic memory, but that
even after the addition of further measures [37] it is a
wholly inadequate assessment of other important
cognitive skills, such as attention, working memory, and
aspects of executive function, especially in very early
stage patients. Whilst it includes measures of language
and praxis, they could in no sense be described as ‘sensi-
tive neuropsychological measures’. Previously reported
studies of very early stage patients have highlighted that
performance on the majority of ADAS-cog subtests is at
ceiling [17] and likely to stay there for the typical
Table 1 Cognitive domains by instrument (# = Prone to ceiling (+) or floor (−) effects in mild stage patients)
Cognitive skill or domain ADAS-cog subtest ADCS-PACC Catch-Cog
Episodic verbal memory test Immediate Word Recall FCSRT/MMSE Immediate Word Recall
Confrontation naming Naming Fingers and Objects # (+) MMSE –
Tests comprehension and praxis Commands # (+) MMSE –
Episodic verbal memory test Delayed Word Recall # (−) Logical Memory/MMSE –
Design copy Constructional Praxis # (+) MMSE –
Familiar task execution Ideational Praxis # (+) MMSE –
Semantic & episodic memory Orientation MMSE Orientation
Episodic verbal memory test Word Recognition – Word Recognition
Episodic memory Remembering Test Instructions # (+) – –
Language production Spoken Language Ability # (+) MMSE –
Semantic memory Word-finding Difficulty # (+) MMSE –
Language comprehension Language Comprehension # (+) MMSE –
Attention Number Cancellation # (+) DSST DSST
Executive skills Maze # (+) DSST DSST, COWAT, CFT, DS
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duration of most clinical trials featuring mild stage pa-
tients [38]. Abandoning the ADAS-cog for superior
measures is long overdue and the quality of our clinical
science will likely be enhanced by making the shift to
more reliable, sensitive and valid measures.
Conclusions
This new guidance offers welcome and helpful details of
the FDA’s thinking with respect to the relationship be-
tween function and cognition, as well as the need for
sensitive neuropsychological assessment. There is also
helpful acknowledgement that the tools needed to deter-
mine efficacy will vary as a function of disease severity.
Whilst still a draft document, it is encouraging to see
the agency offering thoughtful guidance. This guidance
appears to endorse the view that judicious cognitive
domain targeting, wed to the selection of sensitive
neuropsychological and cognitive measures, has the
potential to demonstrate treatment efficacy in the very
earliest detectable stages of AD.
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